All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

31

2023 to 2026

Breakthrough

3

Accelerated

2

Priority review

21

Orphan

5

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202351
202472
202553
202671

31 approvals

Newest first. Hover a badge for what it means.

  • Hibsago (Bepirovirsen Sodium) · GlaxosmithklineOct 20, 2026
    Original approval · NDA 221276NovelPriority reviewApproval letter

    To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

  • Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectOct 9, 2026
    Original approval · NDA 221154NovelPriority reviewApproval letter

    To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

  • Utebzi (Tebipenem Pivoxil Hydrobromide) · GlaxosmithklineJun 17, 2026
    Original approval · NDA 215960NovelPriority reviewApproval letter

    To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

  • Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AGMay 29, 2026
    Original approval · NDA 220787NovelPriority reviewApproval letter

    To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

  • Xocova (Ensitrelvir) · ShionogiMay 29, 2026
    Original approval · NDA 220442NovelApproval letter

    To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19

  • Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026
    Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

  • Idvynso (Doravirine, Islatravir) · MsdApr 20, 2026
    Original approval · NDA 216964NovelApproval letter

    To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

  • Favlyxa (Fluorouracil) · Avyxa HoldingsFeb 20, 2026
    Original approval · NDA 220201Approval letter
  • Nuzolvence (Zoliflodacin) · Entasis TherapDec 12, 2025
    Original approval · NDA 219491NovelPriority reviewApproval letter

    To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae

  • Clotic (Clotrimazole) · Carwin Pharm AssocSep 26, 2025
    Original approval · NDA 217628Priority reviewOrphanApproval letter
  • Inlexzo (Gemcitabine Hydrochloride) · Janssen BiotechSep 9, 2025
    Original approval · NDA 219683Breakthrough therapyPriority reviewApproval letter
  • Enflonsia (Clesrovimab-Cfor) · Merck Sharp DohmeJun 9, 2025
    Original approval · BLA 761432NovelPriority reviewApproval letter

    To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season

  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025
    Original approval · BLA 761373Approval letter
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025
    Original approval · BLA 761425Approval letter
  • Blujepa (Gepotidacin Mesylate) · GlaxosmithklineMar 25, 2025
    Original approval · NDA 218230NovelPriority reviewApproval letter

    To treat uncomplicated urinary tract infections

  • Emblaveo (Avibactam Sodium, Aztreonam) · AbbvieFeb 7, 2025
    Original approval · NDA 217906Priority reviewApproval letter
  • Daptomycin (Daptomycin) · Maia Pharms INCNov 21, 2024
    Original approval · NDA 217630Approval letter
  • Orlynvah (Probenecid, Sulopenem Etzadroxil) · Iterum TherapOct 25, 2024
    Original approval · NDA 213972NovelPriority reviewApproval letter

    To treat uncomplicated urinary tract infections (uUTI)

  • Prevymis (Letermovir) · MsdAug 30, 2024
    Original approval · NDA 219104Priority reviewOrphanApproval letter
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024
    Original approval · BLA 761373Approval letter
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024
    Original approval · BLA 761425Approval letter
  • Xolremdi (Mavorixafor) · X4 PharmsApr 26, 2024
    Original approval · NDA 218709NovelPriority reviewOrphanApproval letter

    To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)

  • Zevtera (Ceftobiprole Medocaril Sodium) · IstxApr 3, 2024
    Original approval · NDA 218275NovelPriority reviewApproval letter

    To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia

  • Rezdiffra (Resmetirom) · MadrigalMar 14, 2024
    Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

  • Exblifep (Cefepime Hydrochloride, Enmetazobactam) · Orchid PharmaFeb 22, 2024
    Original approval · NDA 216165NovelPriority reviewApproval letter

    To treat complicated urinary tract infections

  • Defencath (Heparin Sodium, Taurolidine) · CormedixNov 15, 2023
    Original approval · NDA 214520NovelPriority reviewApproval letter

    To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter

  • Beyfortus (Nirsevimab-Alip) · Astrazeneca AbJul 17, 2023
    Original approval · BLA 761328NovelApproval letter

    To prevent respiratory syncytial virus (RSV) lower respiratory tract disease

  • Paxlovid (Copackaged) (Nirmatrelvir, Ritonavir) · PfizerMay 25, 2023
    Original approval · NDA 217188NovelPriority reviewApproval letter

    To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19

  • Xacduro (Copackaged) (Durlobactam Sodium, Sulbactam Sodium) · Entasis TherapMay 23, 2023
    Original approval · NDA 216974NovelPriority reviewApproval letter

    To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex

  • Rezzayo (Rezafungin Acetate) · MundipharmaMar 22, 2023
    Original approval · NDA 217417NovelPriority reviewOrphanApproval letter

    To treat candidemia and invasive candidiasis

  • Daptomycin (Daptomycin) · HikmaJan 30, 2023
    Original approval · NDA 217415Approval letter

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.